+ Stock Options
More information about location
Digital tools for clinical trials
Job no longer available
Digital tools for clinical trials
201-500 employees
Job no longer available
+ Stock Options
More information about location
201-500 employees
To pave the way to faster, predictable, and more accessible clinical trials.
Clinical research remains a significant bottleneck on drug development. Much of this is due to the slow and unpredictable nature of patient enrolment. OneStudyTeam is tackling this problem with a platform that helps biopharma companies and research sites to enroll trials in three to four months instead of 18 months.
The company's tools are already being used by top-20 global biopharma companies such as Amgen, AstraZeneca, and Eli Lilly & Company, and across a total of over 5,000 research sites across 65 countries. In 2022, OneStudyTeam invested $220 million into improving diversity in clinical trials. This is a strong indicator of the company’s future-facing outlook and its impressive financial backing.
The business is scaling fast, reaching Unicorn status with its Series C round in 2021 and expanding its reach to 10,000 research sites globally. If this trajectory continues, OneStudyTeam could become one of the leading names in the pharmaceutical and healthcare industries.
Kirsty
Company Specialist at Welcome to the Jungle
-34% employee growth in 12 months
Apr 2022
$220m
SERIES D
Aug 2021
$220m
SERIES C
Downtown Crossing, Boston, MA
Ralph Passarella
(CEO & Co-Founder)Founded Reify Health in 2012 whilst completing a PhD/MD at The Johns Hopkins University School of Medicine. Also Co-Founder and Board Member at Signal Vine.
Share this job